Kornimate/medical-research-clean huggingface dataset:
effects of reflexology on postpartum pain, fatigue, sleep quality and lactation

Conditions: Breast Feeding; Fatigue; Sleep; Pain, Postoperative

Summary: the aim of this research is to determine the effect of foot reflexology applied to primiparous women who had cesarean section in the postpartum period on pain, fatigue, sleep quality and lactation. this research is a randomized controlled trial. the study was conducted in şanlıurfa, which has the highest fertility rate in turkey.

the aim of this research is to determine the effect of foot reflexology applied to primiparous women who had cesarean section in the postpartum period on pain, fatigue, sleep quality and lactation. this research is a randomized controlled trial. the study was conducted in şanlıurfa, which has the highest fertility rate in turkey. the sample of the research consisted of 80 primiparous women (reflexology group: 40 and control group: 40). the data were collected between 01 january 2020 - 31 january 2021. "introductory information form", "visual analogue scale" for pain, "visual analog scale for fatigue", "pittsburg sleep quality index" and "bristol breastfeeding assessment tool" were used as data collection tools. foot reflexology was applied to the experimental group for 40 minutes (left foot 20 minutes and right foot 20 minutes) once a week for postpartum 8 weeks. the control group was only watched. in the intergroup comparison of the experimental and control groups, chi-square for categorical variables and independent groups t-test for numerical variables were used. two-way repeated measures anova test was performed in terms of time and group interaction in repeated measurements

Eligibility criteria:
inclusion criteria: * caesarean section, * primipary, * 19 and over and under 35 * literate, * 37 and above pregnancy week * giving birth singularly, * having spinal anesthesia * no chronic disease or pregnancy complication, * have no breast-related health problems * have not had an operation related to the breast, * women who do not have any health problems in the feet of the mothers in the treatment group exclusion criteria: * the baby has died or is not present, * multiparous, * women with health problems in their feet

Keywords: fatigue lactation pain postpartum sleep quality reflexology
feasibility of saliva and remote monitoring of active cytomegalovirus (cmv) infection and symptoms during ovarian cancer treatment

Conditions: Cancer-related Cognitive Dysfunction; Cytomegaloviral Infection; Fallopian Tube Carcinoma; Ovarian Carcinoma; Primary Peritoneal Carcinoma

Summary: this study evaluates the feasibility and accuracy of using saliva to remotely monitor cytomegalovirus (cmv) infection in individuals receiving treatment for ovarian cancer.


Eligibility criteria:
inclusion criteria: * age ≥ 18 * ability to read and write in english * diagnosed with ovarian cancer (ovarian, primary peritoneal, fallopian tube) * receiving care from providers at mayo clinic * regardless of diseases status, actively receiving treatment for ovarian cancer (frontline, maintenance, progression, recurrence) exclusion criteria: * pregnant at the time of study participation * inability to provide informed written consent * history of dementia, stroke, brain tumors or other condition which may impair cognitive functioning
testing the interactive effects of delta-9-tetrahydrocannabinol and pregnenolone: sub-study i

Conditions: Healthy

Summary: the overall purpose of this study is to examine the effect of pregnenolone (preg) on the acute psychosis-like and cognitive effects of delta-9-tetrahydrocannabinol (thc). this will be tested by pretreating healthy individuals with preg, and then assessing their responses to dronabinol (thc).


Eligibility criteria:
inclusion criteria: * exposed to cannabis at least once in lifetime exclusion criteria: * cannabis naïve * individuals with a documented reaction/allergy to pregnenolone * individuals with a documented reaction/allergy to sesame oil

Keywords: cannabis marijuana thc dronabinol pregnenolone preg psychotic disorders
prevalence and clinical characteristics of the fungal nail and feet infection in patients with hallux valgus

Conditions: Acquired Hallux Valgus

Summary: this study was designed to demonstrate the prevalence of onychomycosis in hallux valgus patients. additionally, all the prevalence of tinea pedis, the pattern of clinical manifestations, risk factors and coexistence foot deformities with hallux valgus were observed and recorded.

hallux valgus is an abnormal deviation of the big toe away from the midline of the body or toward the other toes of the foot that is associated especially with the wearing of ill-fitting shoes-compare bunion. according to the previous studies, the association of nails and feet of disorder such as superficial fugal foot infection, abnormal nail shape and onychomycosis was reported. nevertheless, nail disorders have been neglected for examination and treatment due to asymptomatic clinical manifestations and low effects in quality of life, even though it is the common dermatologic problem in general population. nail disorders that coincidentally happen with foot deformities can cause by either onychomycosis or nail trauma. unfortunately, clinical presentation of them is similar. nevertheless onychomycosis is the common superficial fungal infection in thai population. so that the empirical systemic treatment of onychomycosis in older patients by systemic therapy such as azoles group and terbinafine according to the standard regimen maybe induce serious side effects. if onychomycosis is suspected, the abnormal nail should be taken to confirm the diagnosis will be required. therefore, this study was designed to demonstrate the prevalence of onychomycosis in hallux valgus patients. additionally, all the prevalence of tinea pedis, the pattern of clinical manifestations, risk factors and coexistence foot deformities with hallux valgus were observed and recorded.

Eligibility criteria:
inclusion criteria: * male or female participants was 18 years old or above. * participants were diagnosed hallux valgus foot deformity by specialists of physical medicine and rehabilitation based on clinical presentation at foot clinic, siriraj hospital * participants accept the aim of this project and sign the consent form by themselves. exclusion criteria: * participants have other nail disorders before participate the research. * participants have the history of fungal infection treatment with one-month by topical or systemic therapy. * participants have coincidental bacterial infection.

Keywords: fungal nails and feet infection onychomycosis hallux valgus
an effectiveness and safety study of pd 0299685 for the treatment of symptoms associated with interstitial cystitis

Conditions: Interstitial Cystitis; Painful Bladder Syndrome

Summary: the purpose of this study is to determine whether pd 0299685 is effective in the treatment of symptoms associated with interstitial cystitis/painful bladder syndrome, such as pain, urinary urgency and frequency. at the same time assess the drug's safety and tolerability.


Eligibility criteria:
inclusion criteria: * men and women over 18 years of age with moderate to severe interstitial cystitis defined by pain score. * women must not be pregnant or lactating, they may be post-menopausal, surgically sterilized or using an appropriate method of contraception. exclusion criteria: * history of interstitial cystitis less than 6 months * history of current or recurrent urinary tract infections, or genitourinary cancer * any previous urinary diversion procedure with or without bladder removal, bladder augmentation * use of certain drugs given into the bladder up to 1 month prior to study entry
mtd, safety and efficacy of nyh817g and nyh100p in monotherapy and combination in patients with advanced solid tumors

Conditions: Advanced Solid Tumors

Summary: the objectives of this study are: part 1: * to assess the mtd, safety and efficacy of each nyh817g and nyh100p in monotherapy in patients with advanced solid tumors who have failed approved standard therapies. * to assess the pk properties and the preliminary effectiveness of monotherapy of nyh817g and nyh100p. part 2: * to assess the mtd, rp2d, safety and efficacy of nyh817g and nyh100p in combination therapy in patients with advanced solid tumors who have failed approved standard therapies * to assess the pk properties, the preliminary effectiveness and the changes in metabolism of combination therapy of nyh817g and nyh100p.


Eligibility criteria:
inclusion criteria: * 19+ years old * diagnosed with advanced solid tumor histologically/cytologically * patient without standard therapies or who have failed approved standard therapies * those with a disease that is measurable and/or evaluable with the appropriate imaging examination according to recist v1.1 * ecog performance status 0 to 2 * patients with the suitable marrow, kidney, liver functions, blood coagulation and glycemic control functions * patients whose life expectancy is over 12 weeks * patients who signed the agreement to voluntarily participate in this study exclusion criteria: * patients who have received a major surgery, radiotherapy, chemotherapy, biologic therapy, targeted therapy, cancer immunotherapy or metabolic therapy within specified weeks counting from the initial administration of the ips * diagnosed with a malignant tumor other than the relevant disease in the last 5 years from the initial administration of the ips * toxicity level has not been recovered to ctcae grade 1 or lower * has uncontrolled metastasis to the cns * suspected of having a serious infectious disease, paralysis of intestine, bowel obstruction, interstitial pneumonia or pulmonary fibrosis * had serious gi bleed or a disease that may affect the absorption of the oral drug in the past 4 weeks * considered as having a serious heart disease by the investigator or a serious internal disease * has administered a drug from another study within 4 weeks * has administered live vaccines within 4 weeks * has abused substance or alcohol within 12 weeks * has a serious trauma * has a history or currently has a type 1 or 2 diabetes * has a history of lactic acidosis * has glucose-6-phosphate dehydrogenase deficiency * has hiv or active or an active hepatitis b or c * has a history of psychological condition that could threaten observation of this protocol * has a history of hypersensitive reaction to the main ingredient or component of the ip or biguanide class drugs * being pregnant or a lactating woman, or (+) pregnancy test * a female subject of a childbearing age who plans to get pregnant or disagrees to use recommended contraceptions * has not agreed to abstain from alcohol * considered as unsuitable for the study for other reason by the investigator

Keywords: solid tumors failed approved standard therapies advanced solid tumors
unity 1: a study of an investigational treatment regimen of daclatasvir (dcv) + asunaprevir (asv) + bms-791325 in a fixed dose combination (the dcv 3daa (direct acting antiviral) regimen) for 12 weeks for the treatment of chronic hepatitis c virus (hcv) genotype 1 infection in non-cirrhotic subjects

Conditions: Hepatitis C

Summary: to demonstrate the effectiveness of dcv 3daa fixed dose regimen in treatment naive and treatment experienced non-cirrhotic subjects


Eligibility criteria:
for more information regarding bms clinical trial participation, please visit www.bmsstudyconnect.com inclusion criteria: * subjects chronically infected with hcv genotype 1 * hcv rna ≥ 10,000 iu/ml at screening * treatment-naïve subjects with no previous exposure to an interferon formulation (ie, ifnα, pegifnα), rbv, or hcv daa (protease, polymerase inhibitor, etc.) * treatment-experienced subjects are eligible exclusion criteria: * evidence of cirrhosis * liver or any other organ transplant * current or known history of cancer within 5 years prior to enrollment * documented or suspected hcc * evidence of decompensated liver
napoli-2: fluorouracil, leucovorin, and nanoliposomal irinotecan in biliary cancer

Conditions: Advanced Biliary Tract Cancer

Summary: this is a study to evaluate the clinical activity of the combination of fluorouracil, leucovorin, and nanoliposomal irinotecan as second-line treatment in patients with advanced biliary tract cancers following gemcitabine and platinum chemotherapy.

this is a single arm, open label, multicenter phase ii study to evaluate the clinical activity of the combination of fluorouracil, leucovorin, and nanoliposomal irinotecan as second-line treatment in patients with advanced biliary tract cancers following gemcitabine and platinum chemotherapy. patients with advanced biliary tract cancers who have adequate performance status and adequate hepatic and renal function will be eligible. patients may have received adjuvant chemotherapy and/or radiation therapy prior to enrolling in the trial, but a minimum of 6 months between adjuvant chemotherapy and this current therapy are required. patients may continue on study as long as they are tolerating treatment and do not have progression of disease by recist v1.1 criteria. response assessments will occur using imaging (ct or mri) every 8 weeks.

Eligibility criteria:
inclusion criteria: * pathologically-confirmed biliary tract cancer (cholangiocarcinoma or gallbladder adenocarcinoma), unresectable or metastatic * disease progression on or intolerance of gemcitabine- and platinum-based chemotherapy * no more than 1 prior line of chemotherapy for unresectable or metastatic disease (adjuvant therapy does not count) * measurable disease by recist v1.1 criteria * ecog performance status of 0-1 * at least 18 years of age * hiv-positive patients are eligible provided: stable haart regimen, no concurrent prophylactic antibiotics or antifungals, and cd4 count above 250 and undetectable viral load * adequate bone marrow, hepatic, and renal function * consent to access archived tumor tissue if available (available tissue is not required for enrollment) exclusion criteria: * ampullary adenocarcinoma * woman who are pregnant or breastfeeding * anti-cancer treatment within 3 weeks prior to enrollment * prior irinotecan or nanoliposomal irinotecan * central nervous system metastases unless stable for at least 4 weeks and at least 2 weeks off corticosteroids * exposure to a strong cyp3a4 inducer, strong cyp3a4 inhibitor, or strong ugt1a1 inhibitor within 2 weeks of study start * known concurrent malignancy or other malignancy within 3 years except for non-melanomatous skin cancers, prostate or cervical cancers following curative therapy, or superficial bladder cancer * bowel obstruction * allergy or hypersensitivity to fluoropyrimidines, irinotecan, or nanoliposomal irinotecan * clinically significant liver disease: patients with resolved hepatitis b infection are eligible if hbsag testing is negative; patients with resolved hepatitis c infection are eligible if viral rna pcr is negative * severe infections within 4 weeks prior to enrollment * major surgery within 4 weeks prior to enrollment

Keywords: advanced biliary tract cancer biliary tract cancer gi cancer biliary cancer napoli-2
efficacy of gamification in enhancing user engagement

Conditions: Alzheimer Disease; Dementia; Gamification; Assistive Technology

Summary: as part of phase ii of the nih sbir grant, the study will conduct a randomized controlled clinical trial in which the maphabit system's gamification is investigated to determine whether the assistive technology facilitates user engagement and retention. additionally, the study will examine if the gamified software improves the quality of life of persons with dementia and reduce the burden of the respective care partners. participants will be individuals with alzheimer's disease or related dementias in mild to moderate stage of cognitive impairment, in tandem with their respective care partner (i.e., primary familial caregiver). the study will be a randomized controlled clinical trial, in which three conditions will be investigated: 1) experimental condition in which mhs+g is implemented into the daily care received by participants 2) control condition in which the mhs alone is incorporated into the participant's daily care 3) exploratory condition where virtual reality gamification is incorporated into the mhs+g experience. the sample size will be a total of 40 individual-caregiver dyads, 20 in each condition-5 of the 20 subjects in the experimental condition will be included in exploratory condition. the study duration will be a 6-month intervention.


Eligibility criteria:
inclusion criteria: * individual diagnosed with alzheimer's disease or other related dementia (adrd) in their mild to moderate stage of impairment * participating caregiver of individual with dementia must be the primary caregiver * proficient in english exclusion criteria: * individual not diagnosed with adrd * participating caregiver of individual with dementia is not the primary caregiver * not proficient in english

Keywords: alzheimer disease dementia caregiver burden activities of daily living assistive technology
research on the application and mechanism of new biological probes in biomedicine

Conditions: Tumors; Cardiovascular Diseases; Respiratory System Diseases; Digestive System Diseases; Endocrine System Diseases; Metabolic Diseases; Immune System Diseases; Urinary System Diseases; Nervous System Diseases; Blood Diseases; Infectious Diseases

Summary: fluorescence is one of the most commonly used research and detection techniques in the field of biomedical science. the characteristics of fluorescent probe directly affect the performance and application of fluorescence analysis and imaging. aggregation-caused quenching has limited the application of traditional fluorescent probes to some extent. this project intends to systematically evaluate the detection efficiency of new methods through the detection of biomarkers in clinical samples and the comparison with the detection methods of traditional biomarkers, so as to provide theoretical and experimental basis for the establishment of fast and simple biomarker detection technologies with new biological probes.


Eligibility criteria:
inclusion criteria: * sign the informed consent form voluntarily. * age 18-70 years old. * high expression (positive) group: the results of multiple laboratory tests indicate that the marker is higher than the normal range. * low expression (negative) healthy volunteer group: those with no underlying diseases and no abnormalities in the physical examination. * have routine examination to check the remaining body fluid samples, and the body fluid samples are not contaminated. exclusion criteria: * accompanied by other inflammations. * the data of the subject is not complete, or the collection of cases is incomplete due to other reasons. * the researcher judged that it was not suitable to participate in this research.
virtual reality exposure for public speaking anxiety

Conditions: Public Speaking Anxiety

Summary: this study aims to examine the efficacy of exposure using virtual reality (vr) for public speaking anxiety in young adults in two treatment arms: a one-session vr exposure therapy with a 4-week online transition intervention versus a three-session vr exposure therapy with a 4-week online transition intervention. previous studies have demonstrated that one-session therapy (ost) is comparable to prolonged exposure-based therapies in terms of effectively reducing public speaking anxiety. moreover, vr offers many benefits compared to in-person exposure, namely the ability to produce anxiety-evoking stimuli without having to leave the therapist's room. however, ost vr exposure has not been directly compared to prolonged vr exposure and not for public speaking anxiety.


Eligibility criteria:
inclusion criteria: * aged 18-30 and studying in higher education; * experiencing a significant level of public speaking anxiety (60+ on psas); * able to use a computer and have access to the internet for the duration of the study; * able to understand, write and speak in lithuanian; * available to participate in one or three in-person intervention sessions and can devote the time to participate in a 4-week online program following the intervention sessions. exclusion criteria: * a history of seizures or a history of epilepsy; * other significant medical conditions that would prevent them from participating in the program; * high levels of depression (patient health questionnaire-9 rating of 15 and above and mentions of suicidal ideation) or other significant psychiatric conditions that would interfere with participation in the program; * a tendency to have extreme seasickness reactions or a history of adverse physical reactions to virtual reality experiences or difficulty with or lack of stereoscopic vision; * current involvement in other psychological interventions such as psychological counseling or psychotherapy; * use of psychoactive drugs, unless stable for three months; * current participation in other programs aimed at reducing public speaking anxiety.

Keywords: public speaking anxiety virtual reality social anxiety psychological intervention exposure
immunity against varicella in pediatric orthotopic liver transplantation recipients

Conditions: Liver Disease; Immunosuppression; Varicella

Summary: varicella is a vaccine-preventable disease, which can be severe in immunosuppressed children. currently, the (live) vaccine is not recommended in pediatric orthotopic liver transplant recipients. furthermore, protection due to naturally acquired immunity to vzv or post-immunization isn't well described in this population.the questions asked are: * what is the influence of the immunosuppression required after orthotopic liver transplantation (olt) on the maintenance of vzv-specific immunity elicited by wild-type varicella infection before olt transplantation? * what is the influence of the immunosuppression required after olt on vzv-specific immunity elicited by varicella immunization before olt transplantation? * what is the influence of the residual immunosuppression at ≥ 12 months after olt transplantation on the induction of vzv-specific b and t cell responses elicited by vzv vaccination after olt transplantation? * what is the influence of the residual immunosuppression at ≥ 12 months after olt transplantation on the persistence / waning of b and t cell responses elicited by vzv vaccination?

vzv vaccine given to pediatric liver transplant recipients at least one year after transplantation if tehy fulfill inclusion criteria and give informed consent.

Eligibility criteria:
inclusion criteria: * children either awaiting or recipients of a liver transplantation followed at the children's hospital of geneva, switzerland * if vaccination offered: \> 12 months of age exclusion criteria: * known wild type varicella exposure within four weeks of the initial vaccine * immunoglobulins administered within the 5 months preceding the receipt of varicella vaccine. * antiviral agents administered during the preceding 4 weeks * febrile illness (\>38.5°) in the 72 hours before vaccine administration * chronic aspirin therapy * any other live vaccinations within four weeks of receipt of varicella vaccine * female patients in childbearing age will have a pregnancy test at enrollment, and at the time of the second vaccine.

Keywords: orthotopic liver transplantation pediatric immunosuppression varicella vaccine b cell response t cell response antibodies varicella chickenpox transplantation